[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.", "fullTimeEmployees": 65, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 55, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 674000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 56, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": 619101, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2022, "totalPay": 703608, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director & Head of Corporate Communications", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient Advocacy & External Affairs Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.8, "open": 2.79, "dayLow": 2.62, "dayHigh": 2.84, "regularMarketPreviousClose": 2.8, "regularMarketOpen": 2.79, "regularMarketDayLow": 2.62, "regularMarketDayHigh": 2.84, "beta": 0.287, "forwardPE": -6.2045455, "volume": 1714397, "regularMarketVolume": 1714397, "averageVolume": 2260848, "averageVolume10days": 4487630, "averageDailyVolume10Day": 4487630, "bid": 2.69, "ask": 2.7, "bidSize": 1100, "askSize": 2900, "marketCap": 510400800, "fiftyTwoWeekLow": 0.5, "fiftyTwoWeekHigh": 3.89, "priceToSalesTrailing12Months": 35.57048, "fiftyDayAverage": 1.8462, "twoHundredDayAverage": 1.737855, "currency": "USD", "enterpriseValue": 419231552, "floatShares": 99963876, "sharesOutstanding": 186960000, "sharesShort": 16295218, "sharesShortPriorMonth": 17486099, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0872, "heldPercentInsiders": 0.24778, "heldPercentInstitutions": 0.69757, "shortRatio": 13.78, "shortPercentOfFloat": 0.1229, "impliedSharesOutstanding": 201294000, "bookValue": -0.263, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -214384992, "trailingEps": -2.87, "forwardEps": -0.44, "enterpriseToRevenue": 29.217, "enterpriseToEbitda": -6.187, "52WeekChange": 1.6666667, "SandP52WeekChange": 0.27220368, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "messageBoardId": "finmb_665948579", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.73, "targetHighPrice": 7.5, "targetLowPrice": 2.0, "targetMeanPrice": 5.61, "targetMedianPrice": 5.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 164278000, "totalCashPerShare": 0.879, "ebitda": -67756000, "totalDebt": 60021000, "quickRatio": 0.91, "currentRatio": 0.952, "totalRevenue": 14349000, "revenuePerShare": 0.185, "returnOnAssets": -0.28123, "freeCashflow": 101991376, "operatingCashflow": -42189000, "grossMargins": 1.0, "operatingMargins": -3.29414, "financialCurrency": "USD", "trailingPegRatio": null}]